Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission (Q84773113)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

main subject

acute myeloid leukemia

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Bor-Sheng Ko

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Ching-Hua Kuo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Tien Hwei-fang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

K-Y Peng

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

W-C Lei

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

W Tsay

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

16 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

527-529

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21844873%20AND%20SRC:MED&resulttype=core&format=json

IDH1 and IDH2 mutations in gliomas

10 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021

IDH2 mutations in patients with D-2-hydroxyglutaric aciduria

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.215

7 January 2021